MedPath

A phase III, open-label, uncontrolled, multicentre, rollover study to assess safety and efficacy of LB03002 administered weekly in adults with growth hormone deficiency.

Active, not recruiting
Conditions
Growth hormone deficiency in adults
MedDRA version: 8.1Level: LLTClassification code 10056438Term: Growth hormone deficiency
Registration Number
EUCTR2006-002278-24-CZ
Lead Sponsor
BioPartners GmbH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Recruiting
Sex
All
Target Recruitment
150
Inclusion Criteria

1) Patients (male and female) who have completed the Visit 8 of preceding main study (BPLG-005) and are willing to continue their participation in an extension study.
2) If female, women of child-bearing potential who are using a reliable method of contraception and be willing to use it throughout the study. A negative urine pregnancy test at Visit 0 is required for females of child-bearing potential.
3) Written informed consent of the patient.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1) Evidence of active malignancy or growth of a previously stable tumor.
2) Benign intracranial hypertension.
3) Evidence of growth of pituitary adenoma or other intracranial tumor within the last 12 months, or patients without MRI or CT data to confirm the tumor stability within the last 12 months. (footnote: An additional MRI or CT scan will be conducted to confirm the tumor stability if a patient meets other inclusion and exclusion criteria, but DOES NOT have MRI or CT date within last 12 months to confirm th etumor stbility.)
4) Non-compliance with medications, un-cooperativeness or drug abuse during the BPLG-005 study.
5) Patients who are not able to comply with the study protocol for any reason.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath